The FDA approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo, a biosimilar to Humira, in a pre-filled syringe for treating chronic inflammatory diseases.

A biosimilar version of AbbVie Inc.’s blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc. and Samsung Biologics, was approved by EU regulators.

Celgene Corp. said its oral drug to treat relapsing multiple sclerosis met the main goal in a second late-stage study.

While there were definitely positive items in Biogen’s third-quarter 2016 report, the company also threw in what almost seemed like an afterthought – it was no longer developing amiselimod (MT-1303).

Pfizer will begin shipping its biosimilar version of J&J’s rheumatoid arthritis drug Remicade in late November 2016 at a 15% discount to current wholesale prices.

Following a disappointing review of interim data from a clinical study of GS-5745, an investigational anti-MMP9 antibody, Gilead said the company will halt the trial.

AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.

Takeda will refocus R&D on three targeted therapeutic areas – oncology, gastroenterology and CNS. Vaccines will also continue to play an important role.

While Seres has seen explosive headcount growth over the past year, the company is planning for more. Seres is expanding its physical footprint in Cambridge and hiring more staff.

January 28, 2016 By Mark Terry, BioSpace.com Breaking News Staff   Cambridge, Mass.-based Biogen Inc. (BIIB) announced its 2015 financial and fourth-quarter reporting yesterday, citing $10.8 billion in annual revenues, an increase of 11 percent over 2014. Biogen exceeded analysts expectations, who were predicting a revenue increase of about 9 percent. Net income was $3.6 […]